Abstract:Voltage-gated potassium channels are expressed throughout the human body and are essential for physiological functions. These include delayed rectifiers, A-type channels, outward rectifiers, and inward rectifiers. They impact electrical function in the heart (repolarization) and brain (repolarization and stabilization of the resting membrane potential). KCNQx and KCNHx encode Kv7.x and Kv11.x proteins, which form delayed rectifier potassium channels. KCNQx and KCNHx channelopathies are associated with both cardiac and neuronal pathologies. These include electrocardiographic abnormalities, cardiac arrhythmias, sudden cardiac death (SCD), epileptiform discharges, seizures, bipolar disorder, and sudden unexpected death in epilepsy (SUDEP). Due to the ubiquitous expression of KCNQx and KCNHx channels, abnormalities in their function can be particularly harmful, increasing the risk of sudden death. For example, KCNH2 variants have a dual role in both cardiac and neuronal pathologies, whereas KCNQ2 and KCNQ3 variants are associated with severe and refractory epilepsy. Recurrent and uncontrolled seizures lead to secondary abnormalities, which include autonomics, cardiac electrical function, respiratory drive, and neuronal electrical activity. Even with a wide array of anti-seizure therapies available on the market, one-third of the more than 70 million people worldwide with epilepsy have uncontrolled seizures (i.e., intractable/drug-resistant epilepsy), which negatively impact neurodevelopment and quality of life. To capture the current state of the field, this review examines KCNQx and KCNHx expression patterns and electrical function in the brain and heart. In addition, it discusses several KCNQx and KCNHx variants that have been clinically and electrophysiologically characterized. Because these channel variants are associated with multi-system pathologies, such as epileptogenesis, Kv7 channel modulators provide a potential anti-seizure therapy, particularly for people with intractable epilepsy. Ultimately an increased understanding of the role of Kv channels throughout the body will fuel the development of innovative, safe, and effective therapies for people at a high risk of sudden death (SCD and SUDEP).

Voltage-gated potassium channel antibody-mediated syndromes: a spectrum of clinical manifestations

[Voltage-Gated Potassium Channels (VGKC) Complex-Associated Disorders: Anti-LGI1 Encephalitis and Anti-Caspr2 Encephalitis]

Neuromyotonia

Voltage-gated potassium channels as a potential therapeutic target for the treatment of neurological and psychiatric disorders

Autoantibody-mediated central nervous system channelopathies

Neurocardiac pathologies associated with potassium channelopathies

Molecular dissection of an immunodominant epitope in Kv1.2-exclusive autoimmunity

Case report: Varicella associated neuropsychiatric syndrome (VANS) in two pediatric cases

Autoimmune neuromyotonia

Immunotherapy Responsive Autoimmune Subacute Encephalitis: A Report of Two Cases

Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments

Voltage-gated potassium channels and genetic epilepsy

Roles of KCNA2 in Neurological Diseases: from Physiology to Pathology

KCNA2 IgG autoimmunity in neuropsychiatric diseases

Evaluation of four KCNMA1 channelopathy variants on BK channel current under CaV1.2 activation

Antibody-Mediated Nodo- and Paranodopathies

Voltage Gated Calcium Channel Dysregulation May Contribute to Neurological Symptoms in Calmodulinopathies

Determinants of neurological syndromes caused by varicella zoster virus (VZV)

High serum prevalence of autoreactive IgG antibodies against peripheral nerve structures in patients with neurological post-COVID-19 vaccination syndrome

Ion channels-related diseases

Therapeutic role of voltage-gated potassium channels in age-related neurodegenerative diseases